BiQ: 11/23/25 Lyell Immunopharma Upcoming Catalysts (LYEL)

• 12/6/25 Updated LBCL 2L/3L+ data at ASH (12/6 to 12/9)
• 2026 Q1 Initiate pivotal trial for 2L CAR-T Naive LBCL
• 2026 H1 Updated Clinical Data in mCRC 3L+
• 2026 Solid tumor program IND Filing
• 2027 BLA Submission for 3L+ LBCL

LYEL is a speculative, clinical-stage company and not part of the BiQAP.

Please refer to the BiQAP Live spreadsheet on the Active Portfolio page for additional information.

LYEL share price at time of publication: $ 19.13 (BiQ ACB $11.47)

Not a BiQ Premium member, or have a friend who may be interested? Try BiQ Premium for $50 per month, or $250 (50% off) for the first year.

Biotech iQ is 100% subscriber supported. If you find this information helpful, please spread the word. You can also follow me on X @ Biotech iQ (_Biotech_iQ).

Biotech iQ is not an investment professional, and nothing on this page or this website should be considered investment advice. Please consult with a licensed investment professional as necessary. Past performance is not indicative of future results.